Brii Bio to bring Artizan pipeline to China following investment



US-based biotech Artizan Biosciences Inc., announced a collaboration with China’s Brii Biosciences to develop and commercialize up to three of Artizan’s pipeline programs in China. Brii reportedly joined in Artizan’s USD 12 million Series A financing round that was completed this week, although specific investment details were not disclosed.

Artizan is developing therapies using human intestinal microbiota for inflammatory diseases, leveraging its proprietary IgA-SEQ technology platform. The company’s lead program is focused on inflammatory bowel disease (IBD), a group of conditions that include ulcerative colitis and Crohn’s disease. Other potential microbiota-driven diseases include obesity, metabolic syndrome, autoimmune disease, and a variety of skin, lung, liver, and central nervous system diseases. Brii will reportedly bring candidates for China development once they have achieved proof of concept.


Reference:

Related news
Brazil-based laboratory Cristália has invested BRL 150 million (USD 39 million) in the creation of its first oncology active pharmaceutical ingredient (API) production facility.
GT Apeiron, a new artificial intelligence (AI)-driven drug development company, has been established in Shanghai with USD 27 million in financial backing from GT Healthcare Capital Partners, a Chinese private equity fund, and other investors.
Chengdu-based biotech Hinova Pharmaceuticals Inc., trumpeted the receipt of approval from the US FDA to carry out a Phase III clinical trial focused on HC-1119.
  • 1560229978923
  • China
  • Drug
Vivo Capital, a US-based private equity fund focused on healthcare investments in the US and China, issued a filing to the US Securities and Exchange Commission (SEC) indicating that USD 1.28 billion has been raised for a ninth fund.
US-based Oncologie Ltd, an oncology specialist operating between Boston and Shanghai, has reportedly raised USD 80 million via a Series B financing round.
Recent news
Nelson Mussolini, head of Brazil’s Industry Syndicate of Pharmaceutical Products (SINDUSFARMA) and member of the National Health Council, this week voiced his position against the government’s control of drug prices and the high tax rates.
The Center for State Control of Drugs and Medical Devices (CECMED) last week cleared Catalonia (Spain)-based Laboratorio Estedi’s Ursobilane (ursodeoxycholic acid) for the Cuba market, GBI analysis reveals.
According to GBI analysis, Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) this week granted marketing authorization to Japan-based Otsuka Pharmaceutical’s drug-resistant tuberculosis (TB) treatment Deltyba (delamanid).
China-based Sino Biopharmaceutical Ltd (HKEX.01177) announced the signing of a joint venture (JV) agreement between its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd, and Akeso Biopharma Inc​.
A team of Chinese scientists led by Professor Ma Xiong, from Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine (Renji Hospital)'s gastroenterology department, has uncovered the characteristics of intestinal flora in patients with autoimmune hepatitis (AIH), according to the hospital.
  • 1560834410023
  • China
  • R&D
China-based biotechs Tot Biopharm Co., Ltd, and Shanghai Junshi Biosciences Co., Ltd, (HKX.1877) agreed to pair Tot's TAB008, a biosimilar of Roche’s anti-VEGF monoclonal antibody (mAb) bevacizumab (Avastin), in combination with Junshi Bio’s toripalimab (JS001), an innovative recombinant human programmed death-1 (PD-1) monoclonal antibody (mAb).
Colombia’s National Food and Drug Surveillance Institute (INVIMA) this week issued marketing approval to Johnson & Johnson (J&J) subsidiary Janssen’s oral cancer drug Erleada (apalutamide).